Free Trial

OptimizeRx (OPRX) News Today

OptimizeRx logo
$8.37 -0.01 (-0.12%)
As of 11:46 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
OptimizeRx Co. stock logo
Walleye Capital LLC Takes Position in OptimizeRx Co. (NASDAQ:OPRX)
Walleye Capital LLC acquired a new stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 138,575 shares of the company's stock, valued at approximately $673,000. Walleye Cap
Lake Street Sticks to Their Buy Rating for OptimizeRx (OPRX)
Brokerages Set OptimizeRx Co. (NASDAQ:OPRX) PT at $9.06
OptimizeRx Co. stock logo
Kennedy Capital Management LLC Acquires 217,676 Shares of OptimizeRx Co. (NASDAQ:OPRX)
Kennedy Capital Management LLC increased its holdings in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 57.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 594,000 shares of the company's stock after acquiring an add
OptimizeRx Co. stock logo
OptimizeRx Co. (NASDAQ:OPRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) have received an average rating of "Moderate Buy" from the nine analysts that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and
OptimizeRx Co. stock logo
Whetstone Capital Advisors LLC Purchases New Shares in OptimizeRx Co. (NASDAQ:OPRX)
Whetstone Capital Advisors LLC bought a new position in OptimizeRx Co. (NASDAQ:OPRX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,350,423 shares of the company's stock, valued at approximately $6,563,000. OptimizeRx compris
Lake Street Remains a Buy on OptimizeRx (OPRX)
OptimizeRx Co. stock logo
Short Interest in OptimizeRx Co. (NASDAQ:OPRX) Grows By 22.0%
OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) saw a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 1,720,000 shares, a growth of 22.0% from the February 28th total of 1,410,000 shares. Currently, 11.1% of the shares of the stock are short sold. Based on an average trading volume of 502,300 shares, the short-interest ratio is currently 3.4 days.
OptimizeRx Co. stock logo
OptimizeRx Co. (NASDAQ:OPRX) Stake Reduced by Blair William & Co. IL
Blair William & Co. IL trimmed its stake in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 11.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 601,383 shares of the company's stock after selling 75,711 shares during the quarter. Blair William & Co. I
OptimizeRx files $75M mixed securities shelf
OptimizeRx (OPRX) Gets a Buy from Lake Street
OptimizeRx Co. stock logo
Insider Buying: OptimizeRx Co. (NASDAQ:OPRX) Director Purchases 321,408 Shares of Stock
OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) Director James Paul Lang bought 321,408 shares of the stock in a transaction on Friday, March 14th. The shares were acquired at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the purchase, the director now owns 389,452 shares in the company, valued at approximately $2,959,835.20. This represents a 472.35 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
OptimizeRx Co. stock logo
Royce & Associates LP Takes $5.20 Million Position in OptimizeRx Co. (NASDAQ:OPRX)
Royce & Associates LP acquired a new position in OptimizeRx Co. (NASDAQ:OPRX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,069,560 shares of the company's stock, valued at approximately $5,198,000. Ro
OptimizeRx Co. stock logo
OptimizeRx Co. (NASDAQ:OPRX) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine analysts that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and on
OptimizeRx management to meet with Lake Street
OptimizeRx Co. stock logo
OptimizeRx (OPRX) to Release Quarterly Earnings on Wednesday
OptimizeRx (NASDAQ:OPRX) will be releasing earnings after the market closes on Wednesday, March 26, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=671031)
OptimizeRx Co. stock logo
Research Analysts Issue Forecasts for OptimizeRx Q1 Earnings
OptimizeRx Co. (NASDAQ:OPRX - Free Report) - Analysts at Roth Capital issued their Q1 2026 EPS estimates for shares of OptimizeRx in a report issued on Wednesday, March 12th. Roth Capital analyst R. Baldry anticipates that the company will post earnings of ($0.19) per share for the quarter. The c
OptimizeRx Co. stock logo
What is B. Riley's Estimate for OptimizeRx Q1 Earnings?
OptimizeRx Co. (NASDAQ:OPRX - Free Report) - Research analysts at B. Riley issued their Q1 2025 EPS estimates for OptimizeRx in a research note issued to investors on Wednesday, March 12th. B. Riley analyst A. Schock forecasts that the company will earn ($0.34) per share for the quarter. B. Riley
OptimizeRx Co. stock logo
OptimizeRx (NASDAQ:OPRX) Upgraded at B. Riley
B. Riley raised OptimizeRx to a "strong-buy" rating in a research note on Wednesday.
OptimizeRx Co. stock logo
OptimizeRx (NASDAQ:OPRX) Issues Quarterly Earnings Results
OptimizeRx (NASDAQ:OPRX - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.25 by ($0.11). OptimizeRx had a negative return on equity of 4.92% and a negative net margin of 27.41%.
OptimizeRx Q4 results ‘at odds with muted’ outlook, says Roth MKM
OptimizeRx Appoints Steve Silvestro As CEO
OptimizeRx reports Q4 EPS 30c, consensus 27c
OptimizeRx confirems receipt of notice of director nominations
OptimizeRx appoints Silvestro as CEO
Lake Street Reaffirms Their Buy Rating on OptimizeRx (OPRX)
Lake Street Reaffirms Their Buy Rating on OptimizeRx (OPRX)
OptimizeRx Co. stock logo
OptimizeRx (OPRX) Projected to Post Earnings on Wednesday
OptimizeRx (NASDAQ:OPRX) will be releasing earnings before the market opens on Wednesday, March 12, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=671031)
OptimizeRx Co. stock logo
OptimizeRx Co. (NASDAQ:OPRX) Receives Consensus Rating of "Moderate Buy" from Analysts
OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine brokerages that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The
One OptimizeRx Insider Raised Their Stake In The Previous Year
OptimizeRx Co. stock logo
OptimizeRx's (OPRX) "Market Outperform" Rating Reaffirmed at JMP Securities
JMP Securities reiterated a "market outperform" rating and set a $8.00 price objective on shares of OptimizeRx in a report on Thursday.
OptimizeRx Co. stock logo
JPMorgan Chase & Co. Sells 104,750 Shares of OptimizeRx Co. (NASDAQ:OPRX)
JPMorgan Chase & Co. reduced its position in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 93.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,783 shares of the company
OptimizeRx Co. stock logo
OptimizeRx Co. (NASDAQ:OPRX) Receives Average Rating of "Moderate Buy" from Analysts
OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine research firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the compa
OptimizeRx (OPRX) was downgraded to a Hold Rating at Stifel Nicolaus
OptimizeRx downgraded to Sector Perform from Outperform at RBC Capital
Get OptimizeRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.

OPRX Media Mentions By Week

OPRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

OPRX
News Sentiment

0.34

0.75

Average
Computer and Technology
News Sentiment

OPRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

OPRX Articles
This Week

4

2

OPRX Articles
Average Week

Get OptimizeRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:OPRX) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners